A Canadian multicenter, double-blind study of paroxetine and fluoxetine in major depressive disorder
about
Paroxetine versus other anti-depressive agents for depressionFluoxetine versus other types of pharmacotherapy for depressionFluoxetine versus other types of pharmacotherapy for depressionTolerability and safety of fluvoxamine and other antidepressants.A systematic review of the correlates and management of nonpremature ejaculatory dysfunction in heterosexual menComparative effectiveness of second-generation antidepressants for accompanying anxiety, insomnia, and pain in depressed patients: a systematic review.Goals in symptomatic pharmacologic management of frontotemporal lobar degeneration.Emerging treatments for premature ejaculation: focus on dapoxetine.Sexual dysfunction associated with second-generation antidepressants in patients with major depressive disorder: results from a systematic review with network meta-analysis.Comparative efficacy and risk of harms of immediate- versus extended-release second-generation antidepressants: a systematic review with network meta-analysis.International dosage differences in fluoxetine clinical trials.Does differential drop-out explain the influence of study design on antidepressant response? A meta-analysis.Does study design influence outcome?. The effects of placebo control and treatment duration in antidepressant trials.Less is more in antidepressant clinical trials: a meta-analysis of the effect of visit frequency on treatment response and dropout.Comparative efficacies of fluoxetine and paroxetine in major depression across varying acute-phase treatment periods: a meta-analysis.Antidepressants: psychiatrists' opinions and clinical practice.Meta-analysis of placebo rates in major depressive disorder trials.
P2860
Q24197507-130EE181-13B4-490E-A26C-0130C5DD59FBQ24201165-14BF87AE-4426-496E-954C-A230AE548836Q24245764-18286243-EC4E-413D-BB8B-8D82496E7C50Q33995120-58FCB7D0-F7BA-4EC7-B3AC-792A49B05DCFQ34038361-EEE4491A-C138-4C2E-A20F-E02A475329E5Q34254323-74855D6B-8C40-43B0-BC22-2451623C8185Q34976729-5C74CDC6-2170-40FC-A393-B28619079667Q34989184-15DFC6CF-12FD-4EB9-A000-8F30D3FE5825Q35066804-305C4BE3-0962-4294-BA56-A46894F6F0A6Q35162633-62B0158B-E3B6-42A7-B19E-FECAAC577610Q36065042-70F5ECD8-E156-49F6-9BC9-DF189CEEA9BFQ36650741-99B3DC82-3EBF-4E49-9359-45795D258CD3Q37202188-3C32E1DC-5164-4155-8537-D5E8BAADE9BAQ37503551-40B8F1F0-581B-4870-B596-B0E5232BF204Q38154837-E05FB27B-F727-42DD-8E8E-00A1AFE5F85AQ44478458-028FCA82-D9D2-48D3-B639-1B03B5C772E3Q51945431-EF84DCB5-158E-4993-9482-3227C15C0919
P2860
A Canadian multicenter, double-blind study of paroxetine and fluoxetine in major depressive disorder
description
1999 nî lūn-bûn
@nan
1999 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
A Canadian multicenter, double ...... e in major depressive disorder
@ast
A Canadian multicenter, double ...... e in major depressive disorder
@en
A Canadian multicenter, double ...... e in major depressive disorder
@nl
type
label
A Canadian multicenter, double ...... e in major depressive disorder
@ast
A Canadian multicenter, double ...... e in major depressive disorder
@en
A Canadian multicenter, double ...... e in major depressive disorder
@nl
prefLabel
A Canadian multicenter, double ...... e in major depressive disorder
@ast
A Canadian multicenter, double ...... e in major depressive disorder
@en
A Canadian multicenter, double ...... e in major depressive disorder
@nl
P2093
P1476
A Canadian multicenter, double ...... e in major depressive disorder
@en
P2093
A Ravindran
G Chouinard
L Beauclair
M C Bélanger
M C O'Neill
N P Vasavan Nair
R Manchanda
P356
10.1016/S0165-0327(98)00188-8
P407
P577
1999-07-01T00:00:00Z